Frequent reconstitution of IDH2(R140Q) mutant clonal multilineage hematopoiesis following chemotherapy for acute myeloid leukemia.
Authors
Wiseman, Daniel HWilliams, Emma L
Wilks, Deepti P
Leong, Hui Sun
Somerville, Tim D D
Dennis, Michael
Struys, E
Bakkali, A
Salomons, G
Somervaille, Tim C P
Affiliation
Leukaemia Biology Laboratory, Manchester Cancer Research Centre Biobank, Computational Biology, Cancer Research UK Manchester Institute, The University of ManchesterIssue Date
2016-05-13
Metadata
Show full item recordCitation
Frequent reconstitution of IDH2(R140Q) mutant clonal multilineage hematopoiesis following chemotherapy for acute myeloid leukemia. 2016: LeukemiaJournal
LeukemiaDOI
10.1038/leu.2016.93PubMed ID
27118404Type
ArticleLanguage
enISSN
1476-5551ae974a485f413a2113503eed53cd6c53
10.1038/leu.2016.93
Scopus Count
Collections
Related articles
- Genome-scale integrated analysis to identify prospective molecular mechanisms and therapeutic targets in isocitrate dehydrogenase 2 R140Q-mutated acute myeloid leukemia.
- Authors: Huang R, Liao X, Li J, Wei J, Su X, Lai X, Liu B, Zhu F, Huang Y, Li Q
- Issue date: 2019 May
- Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.
- Authors: Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, Hansen E, Straley K, Kernytsky A, Liu W, Gliser C, Yang H, Gross S, Artin E, Saada V, Mylonas E, Quivoron C, Popovici-Muller J, Saunders JO, Salituro FG, Yan S, Murray S, Wei W, Gao Y, Dang L, Dorsch M, Agresta S, Schenkein DP, Biller SA, Su SM, de Botton S, Yen KE
- Issue date: 2013 May 3
- Identification of a selective inhibitor of IDH2/R140Q enzyme that induces cellular differentiation in leukemia cells.
- Authors: Chen J, Yang J, Wei Q, Weng L, Wu F, Shi Y, Cheng X, Cai X, Hu C, Cao P
- Issue date: 2020 Apr 3
- All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells.
- Authors: Kim Y, Jeung HK, Cheong JW, Song J, Bae SH, Lee JI, Min YH
- Issue date: 2020 Sep
- Enasidenib for patients with relapsed acute myeloid leukemia and the IDH2 mutation.
- Authors: DiNardo C
- Issue date: 2018 Apr